Jeffrey Riley, CEO, will present at the LD MICRO VI: Main Event Conference at 9:30 a.m. (PT) on Wednesday, December 4, 2013. The conference will be held December 3-5, 2013 at the Luxe Sunset Bel Air Hotel in Los Angeles. A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://wsw.com/webcast/ldmicro5/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.
SYN-004, Synthetic Biologics' product candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in the infectious disease area by Elsevier Business Intelligence.
Jeffrey Riley, CEO, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19, 2013 at 4:00pm (EST) at the Hyatt Regency in Boston.
Please note, this conference does not provide webcasting.
Synthetic Biologics will hold an investor conference call on Thursday, November 14, 2013, at 10:00 am EST. Interested parties should call 1-877-870-4263 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=96920. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=96920 for 30 days after the call.
Synthetic Biologics' management will be participating at BIO-Europe 2013 in Vienna, Austria.
Jeff Riley, Synthetic Biologics' CEO, will present at the BioJapan 2013 World Business Forum being held on October 9-11, 2013 in Yokohama, Japan. Mr. Riley is scheduled to present at 11:25 a.m. (Japan Standard Time) on Wednesday, October 9, 2013 at Pacifico Yokohama.
Webcasting is not available for this event.
Jeff Riley, Synthetic Biologics' CEO, will present at the First Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to present at 11:15 a.m. (Central European Summer Time)/5:15 a.m. (Eastern Time) on Monday, September 16, 2013 at the Warsaw Stock Exchange.
A live webcast of Synthetic Biologics’ presentation will be available. URL: http://www.wdmcapital.com/en/strony/lsc/live_webcast.html
After the presentation, the archived replay will be available via at the following URL:http://www.wdmcapital.com/en/strony/lsc/live_webcast.html
Jeff Riley, Synthetic Biologics' CEO, will present at the Rodman & Renshaw 15th Annual Healthcare Conference being held at the Millennium Broadway Hotel in New York City on September 9, 2013.
A live webcast of Synthetic Biologics’ presentation will be available. URL: http://wsw.com/webcast/rrshq23/SYN
After the presentation, the archived replay will be available via at the following URL: http://wsw.com/webcast/rrshq23/SYN
Jeff Riley, Synthetic Biologics' CEO, will present at the OneMedForum New York 2013 Conference being held at the Metropolitian Club in New York City on June 27, 2013.
A live webcast of Synthetic Biologics’ presentation will be available. URL: http://onemedplace.com/forum/webcast/
After the presentation, the archived replay will be available via OneMed Fourm at the following URL: http://www.youtube.com/watch?v=IZY6LUQpfrA
SYN: MS-Estriol Investor Day
To access the live webcast, or replay the webcast after the event, please use the following URL: https://viavid.webcasts.com/starthere.jsp?ei=1018556.
Keynote Speaker: Rhonda R. Voskuhl, MD
Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research, Director, Multiple Sclerosis Program, UCLA School of Medicine
Company Speakers: Jeffrey Riley, CEO and Carol Reed, MD, SVP, Clinical & Regulatory Affairs
Synthetic Biologics’ executive management will be joined by Rhonda R. Voskuhl, MD, an expert in multiple sclerosis (MS) and lead investigator of the Phase II clinical trial evaluating the Company’s product candidate, TrimestaTM (oral estriol), for the treatment of relapsing-remitting MS. An overview of MS and the current market, as well as the history of estriol and its role in the treatment of MS will be discussed.